Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic

被引:95
作者
Giordano, TP
White, AC
Sajja, P
Graviss, EA
Arduino, RC
Adu-Oppong, A
Lahart, CJ
Visnegarwala, F
机构
[1] Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA
[2] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[4] Univ Texas, Hlth Sci Ctr, Sch Med, Dept Med,Sect Infect Dis, Houston, TX USA
关键词
highly active antiretroviral therapy; women; adherence; naive patients; appointments; HIV;
D O I
10.1097/00126334-200304010-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ethnic minority, female, and drug-using patients may be less likely to receive highly active antiretroviral therapy (HAART), despite its proven benefits. We reviewed the medical records of a consecutive population of 354 patients entering care in 1998 at the Thomas Street Clinic, an academically affiliated, public, HIV-specialty clinic in Houston, to determine the factors associated with not receiving HAART as recorded in pharmacy records. Ninety-two patients (26.0%) did not receive HAART during at least 6 months of follow-up. Patients who did not receive HAART were more likely to be women and to have missed more than two physician appointments and were less likely to have a CD4 count < 200 cells/muL or a viral load greater than or equal to 10(5) copies/mL. In multivariate logistic analysis, missed appointments (OR = 5.85, p < .0001), female sex (OR = 2.53, p = .001), and CD4 count greater than or equal to 200 cells/muL (OR = 2.50, p = .001) were independent predictors of not receiving HAART. More than half the patients who never received HAART never returned to the clinic after their first appointment. Among patients new to care, women and those with poor appointment adherence were less likely to receive HAART. Efforts to improve clinic retention and further study of the barriers to HAART use in women are needed.
引用
收藏
页码:399 / 405
页数:7
相关论文
共 40 条
[11]   Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women [J].
Cook, JA ;
Cohen, MH ;
Grey, D ;
Kirstein, L ;
Burke, J ;
Anastos, K ;
Palacio, H ;
Richardson, J ;
Wilson, TE ;
Young, M .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2002, 92 (01) :82-87
[12]   Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States [J].
Cunningham, WE ;
Markson, LE ;
Andersen, RM ;
Crystal, SH ;
Fleishman, JA ;
Golin, C ;
Gifford, A ;
Liu, HHH ;
Nakazono, TT ;
Morton, S ;
Bozzette, SA ;
Shapiro, MF ;
Wenger, NS .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (02) :115-123
[13]   The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States [J].
Cunningham, WE ;
Andersen, RM ;
Katz, MH ;
Stein, MD ;
Turner, BJ ;
Crystal, S ;
Zierler, S ;
Kuromiya, K ;
Morton, SC ;
St Clair, P ;
Bozzette, SA ;
Shapiro, MF .
MEDICAL CARE, 1999, 37 (12) :1270-1281
[14]  
*DEP HLTH HUM SERV, 2002, GUID US ANT AG HIV I
[15]   Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration [J].
Detels, R ;
Muñoz, A ;
McFarlane, G ;
Kingsley, LA ;
Margolick, JB ;
Giorgi, J ;
Scharager, LD ;
Phair, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (17) :1497-1503
[16]   Delays in protease inhibitor use in clinical practice [J].
Fairfield, KM ;
Libman, H ;
Davis, RB ;
Eisenberg, DM ;
Phillips, RS .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1999, 14 (07) :395-401
[17]  
Gardner LI, 2002, J ACQ IMMUN DEF SYND, V29, P69, DOI 10.1097/00126334-200201010-00010
[18]   Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy [J].
Hogg, RS ;
Yip, B ;
Chan, KJ ;
Wood, E ;
Craib, KJP ;
O'Shaughnessy, MV ;
Montaner, JSG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (20) :2568-2577
[19]  
Hsu LC, 2001, J ACQ IMMUN DEF SYND, V28, P345, DOI 10.1097/00126334-200112010-00007
[20]   The serostatus approach to fighting the HIV epidemic: Prevention strategies for infected individuals [J].
Janssen, RS ;
Holtgrave, DR ;
Valdiserri, RO ;
Shepherd, M ;
Gayle, HD ;
De Cock, KM .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2001, 91 (07) :1019-1024